Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MVA-SARS-2-S
- Development stage
- Phase 2
- Lead developer
- University Medical Center Hamburg-Eppendorf
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
MVA-SARS-2-S is an investigational COVID-19 vaccine candidate that uses a Modified Vaccinia Virus Ankara (MVA) vector to express the full-length spike (S) protein of SARS-CoV-2. The MVA vector is a highly attenuated, non-replicating poxvirus with a strong safety profile in mammalian hosts. Upon intramuscular administration, the vaccine delivers the SARS-CoV-2 S protein, inducing both humoral and cellular immune responses, including neutralizing antibodies and CD8+ T cells specific for the spike antigen. Preclinical studies have shown that vaccination with MVA-SARS-2-S protects animals from lethal SARS-CoV-2 infection and severe lung pathology by eliciting robust immune responses[1][4][5]. The primary indication is prevention of COVID-19.
- Other names
- MVA-SARS-2-S vaccineMVA-SARS2-S vaccineMVA-SARS 2-S vaccineDZIF COVID-19 vaccineUKE COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on MVA-SARS-2-S.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MVA-SARS-2-S.